Health ❯ Pharmaceuticals ❯ Drug Safety ❯ Abortion Drugs

Mifepristone

Hawley Pressures FDA Chief as Anti‑Abortion Groups Demand Firing Over Reported Mifepristone Review Delay

The FDA describes an evidence‑driven study now in a data‑gathering phase with no projected timeline.

FDA Approves Second Generic Mifepristone as White House Cites Legal Obligation

FDA Opens Mifepristone Safety Review as Republicans Move to Curb Mail and Telehealth Access

FDA Commissioner Pledges Safety Review of Abortion Pill Mifepristone